Diagnosis and treatment of eosinophilic esophagitis

Jonathan Spergel

Address: Division of Allergy and Immunology, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Market Street, Philadelphia, PA 19104-4399, USA

Email: spergel@email.chop.edu

F1000 Medicine Reports 2009, 1:46 (doi:10.3410/M1-46)
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/46

Abstract

Eosinophilic esophagitis is a newer disease entity that has been diagnosed with increasing frequency over the past 10 years. Patients present with a variety of symptoms including vomiting, failure to thrive, abdominal pain, dysphagia, and/or food impaction depending on the age of the patient. The diagnosis is confirmed by endoscopy with eosinophilic inflammation localized to the oesophagus, an area typically void of eosinophils.

Introduction and context

Eosinophilic esophagitis (EE) is a disease entity that has been diagnosed with increasing frequency. The first reported case of EE was in 1977 in an adult patient with food allergies, gastroesophageal reflux disease (GERD) symptoms, and esophageal eosinophilia [1]. The definitive link between food allergies and EE was shown by Dr Kelly and colleagues in 1995 [2], when they described 10 patients with isolated esophageal eosinophilia unresponsive to acid blockade who improved with an elemental formula. In fact, eight had complete normalization of esophageal eosinophilia after 6 weeks. Their findings introduced the role of food allergy in EE [2].

Since the mid-nineties, there has been a dramatic rise in the number of patients diagnosed with EE. EE has now been reported in every continent except for Africa, including every state in the United States and most of Western Europe. Several reports have suggested that the prevalence of EE has increased in both pediatric and adult patients by 18- to 35-fold in the past 20 years [3-6].

What is the general approach to management of eosinophilic esophagitis?

Management of EE involves elimination/control of eosinophils with either medications or diet. Medical treatment involves treating the symptoms but not the cause of the disease. It is important to note that there are no current approved medications for the treatment of EE, however, the use of ‘topical’ corticosteroids has been shown to be successful. The patients typically swallow inhaled corticosteroids used for asthma in moderate to high doses (given without use of spacer and avoiding foods/liquids for 30 minutes). The goal of this therapy is to deposit steroids in the esophagus leading to apoptosis of the eosinophils and reduction of symptoms. These methods have been shown to have a varying rate of success. Konikoff et al. [7] completed a randomized double-blind placebo-controlled trial of 36 pediatric patients with EE who either refused or failed dietary modification. They reported improved control of symptoms and less eosinophils per high power field (eosinophils/HPF) in biopsy in 50% of the patients. The success rate was 50% compared to an 80-90% success rate in the open-label trials with fluticasone or budesonide [8,9].

Cromolyn, montelukast (a leukotriene receptor antagonist), andomalizumab (an anti-IgE antibody), did not show any histological improvement in open-label clinical trials [5,10,11]. At this point, these drugs cannot be recommended for EE. A recent open label trial of mepolizumab (an anti-interleukin (IL)-5 antibody) showed a significant improvement in four patients, with biopsy improving from 150 to 40 eosinophils/HPF; however, this was still well above the normal level of 0 eosinophils/HPF [12].
Dietary approach
A second approach is to treat the cause of EE by eliminating the appropriate food. An elemental diet has been successful in both pediatric and adult patients, with success rates surpassing 95% [5,13]. However, due to the poor palatability of these formulas, it is difficult for patients to remain on them. A more directed approach to eliminating the particular food antigen is possible; two possible ways to remove the food antigen include removing the most common food allergens or removing the allergens based on allergy testing. The first method has been primarily studied by Kagalwalla et al. [14] in pediatric patients and by Gonsalves in adults (N Gonsalves, personal communication). They found that a ‘six-food’ elimination diet [no milk, soy, egg, wheat, seafood (fish and shellfish), and peanuts (peanuts and tree nuts)] led to a significant reduction of esophageal eosinophilia. In their pediatric trial, Kagalwalla et al. [14] started 35 children on the ‘six-food’ elimination diet; 74% of the children had resolution (<10 eosinophils/HPF) on this diet. In adult trials, the success rate is reported to be 50% with the elimination diet and 90-95% for the elemental diet (N Gonsalves, personal communication).

The alternative dietary approach is to remove foods based on allergy testing. Three standard methods are used for food testing: prick skin testing, in vitro specific IgE assays and atopy patch tests. In a study on children, diets based on positive specific IgE assays had a response rate near 0% when foods were eliminated based purely on the in vitro specific IgE assay results [15]. In the same study, the prick skin test had only a slightly better success rate of about 50%. This strongly suggests that the food allergy in EE is not strictly IgE mediated, consistent with the results with omalizumab. Based on this finding, we started to use atopy patch testing for EE [16]. Atopy patch testing is designed to look for non-IgE-mediated food reactions, presumably T cell-mediated. We have found that the combination of both the prick skin and atopy patch tests, looking for both IgE- and non-IgE-mediated disease, has been highly successful in the treatment of EE. A food that was negative on both the prick skin and atopy patch tests was unlikely to cause EE, with a predictive value of 90% or more for all foods except milk [17]. Additionally, the combination of the skin prick and atopy patch tests resulted in resolution of EE symptoms and normalization of biopsies in 80% of patients [17-19].

What is the prognosis?
EE is a chronic disorder. If any treatment, medical or dietary, is stopped, the symptoms return and esophageal eosinophilia reoccurs with very rare exceptions. Longitudinal studies in adults over a 12 year period have not shown resolution [20].

Recent advances
One of the major advances in the past 2 years was the First International Gastrointestinal Eosinophil Research Symposium (FIGERS), a consensus meeting of allergists, gastroenterologists, and pathologists that developed clinical recommendations for the diagnosis and treatment of EE [21]. This group defined EE as a ‘primary clinicopathological disorder of the esophagus’ with diagnosis made by esophageal biopsy with a finding of ≥15 eosinophils/HPF in one or more specimens. The report emphasized that gastroesophageal reflux must be aggressively managed prior to endoscopy with a high dose proton pump inhibitor or the patient must have evidence of normal distal esophageal pH as detected by pH probe; this was based on a case report by Ngo and colleagues [22] describing three patients whose esophageal eosinophil count of up to 52 eosinophils/HPF resolved with reflux medications. Besides gastroesophageal reflux, clinicians must keep in mind that esophageal eosinophils can be seen in other disease entities, including eosinophilic gastroenteritis (increased eosinophils throughout the gastrointestinal tract), Crohn’s disease, collagen vascular disease, hypereosinophilic syndrome, and drug-associated diseases, and are occasionally associated with infections.

Additional recent studies have indicated that EE is a chronic disease, with less than 10% of patients outgrowing it [10,23,24]. The relationship was confirmed in studies in both adults and children, approximately 75% of whom had other atopic diseases (allergic rhinitis, asthma or atopic dermatitis) [25,26] and associations with celiac disease [27-30] and tracheoesophageal fistula [31].

Recent studies have confirmed that symptoms of EE vary by age. Young infants and toddlers typically present with GERD or failure to thrive due to the assumed pain associated with eating. School-age children typically present with abdominal pain or persistent GERD symptoms. The most common symptoms in adolescents and adults include dysphagia and food impaction [3,21,24]. These symptoms are more unusual and should immediately suggest the possibility of EE. These patients were all diagnosed at an early age and were treated aggressively through avoidance of allergens. Because the symptoms of EE do not correlate with endoscopy and histological findings, it is important to use endoscopy for diagnosing and following patients with EE [32].
Several articles by the Rothenberg and Justinich laboratories have made advances in determining the potential mechanism of EE, showing that IL-13 and fibroblast growth factor-9 have important roles in the proliferative responses in the esophagus [33-36]. Straumann et al. [37] examined the use of infliximab (an anti-tumor necrosis factor-α antibody) in treating EE, but it had no effect on histological findings.

Implications for clinical practice
The most recent studies suggest there is a certain phenotype that should be examined carefully for EE. The stereotypical patient is a male Caucasian with classic symptoms (dysphagia or food impaction in adolescents and adults; abdominal pain in school-age children; GERD symptoms in young children). Also, the lack of correlation of symptoms with endoscopy findings indicates the importance of using endoscopy for diagnosing and following patients with EE. Management of this disease is primarily through diet as foods are causative in more than 90% of adults and children. Medical therapies are being developed for patients with restrictive and socially difficult diets.

Abbreviations
EE, eosinophilic esophagitis; GERD, gastroesophageal reflux disease; HPF, high power field; IL, interleukin.

Competing interests
The author was a local principal investigator for multicenter studies by Ception Therapeutics (Rockville, MD, USA) and Nutricia North America (Gaithersburg, MD, USA).

References
1. Dobbins JW, Sheahan DG, Behar J: Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology 1977, 72:1312-6.
2. Kelly K, Lazenby A, Rowe P, Yardley JH, Perman J, Sampson H: Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995, 109:1503-12.
3. Noel RJ, Putnam PE, Rothenberg ME: Eosinophilic esophagitis. N Engl J Med 2004, 351:940-1.
4. Straumann A, Simon HU: Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005, 115:418-9.
5. Liacouras CA, Spergel JM, Ruchelli E, Mascarenhas M, Semeao E, Flick J, Kelly J, Brown-Whitehorn T, Mamula P, Markowitz JE: Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005, 3:1198-206.
6. Cherian S, Smith NM, Forbes DA: Rapidly increasing prevalence of eosinophilic esophagitis in Western Australia. Arch Dis Child 2006, 91:1000-4.
7. Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assaad AH, Aceves SS, Putnam PE, Rothenberg ME: A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006, 131:1381-91.
8. Aceves SS, Dohil R, Newbury RO, Bastian JF: Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2005, 116:705-6.
9. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassell E, Straumann A, Rothenberg ME; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees: Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007, 133:1342-63.
10. Attwood SE, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J: Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003, 52:181-5.
11. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C: Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007, 120:594-601.
12. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, Filipovich AH, Assaad AH, Rothenberg ME: Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006, 118:1312-9.
13. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA: Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003, 98:777-82.
14. Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, Melin-Aldana H, Li BJ: Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006, 4:1097-102.
15. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, Badizadegan K, Furuta GT: Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002, 122:1216-25.
16. Spergel JM, Andrews T, Brown-Whitehorn TF, Beausoleil JL, Liacouras CA: Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005, 95:336-43.
17. Liacouras CA, Spergel JM, Ruchelli E, Liacouras CA: Predictive values for skin prick test and atopy patch test for eosinophilic esophagitis. J Allergy Clin Immunol 2007, 119:509-11.
18. Spergel J, Andrews T, Brown-Whitehorn T, Beausoleil J, Liacouras C: Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of prick test and patch tests. Ann Allergy Asthma Immunol 2005, 95:336-43.
19. Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA: The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002, 109:363-8.
20. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU: Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003, 125:1660-9.
21. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassell E, Straumann A, Rothenberg ME; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees: Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007, 133:1342-63.
series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006, 101:1666-70.

F1000 Factor 3.0 Recommended
Evaluated by Jon Markowitz 31 Aug 2006

23. Assa’ad AH, Putnam PE, Collins MH, Akers RM, Jameson SC, Kirby CL, Buckmeier BK, Bullock JZ, Collier AR, Konikoff MR, Noel RJ, Guajardo JR, Rothenberg ME: Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol 2007, 119:731-8.

24. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, Franciosi J, Shuker M, Verma R, Liacouras CA: 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009, 48:30-6.

25. Veerappan GR, Perry JL, Duncan TJ, Baker TP, Maydonovitch C, Lake JM, Wong RK, Osgard EM: Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol 2008, 7:420-6.

26. Jyonouchi S, Brown-Whitehorn TA, Spergel JM: Association of eosinophilic gastrointestinal disorders with other atopic disorders. Immunol Allergy Clin North Am 2009, 29:85-97.

27. Ooi CY, Day AS, Jackson R, Bohane TD, Tobias V, Lemberg DA: Eosinophilic esophagitis in children with celiac disease. J Gastroenterol Hepatol 2008, 23:1448.

28. Heine RG: Eosinophilic esophagitis in children with celiac disease: new diagnostic and therapeutic dilemmas. J Gastroenterol Hepatol 2008, 23:993-4.

29. Verzegnassi F, Bua J, De Angelis P, Dall’Angelo L, Di Leo G, Ventura A: Eosinophilic oesophagitis and coeliac disease: is it just a casual association? Gut 2007, 56:1029-30.

30. Quaglietta L, Coccorullo P, Miele E, Pascarella F, Troncone R, Staiano A: Eosinophilic esophagitis and coeliac disease: is there an association? Aliment Pharmacol Ther 2007, 26:487-93.

31. Oliveira C, Zamakhshary M, Marcon P, Kim PC: Eosinophilic esophagitis and intermediate esophagitis after tracheoesophageal fistula repair: a case series. J Pediatr Surg 2008, 43:810-4.

32. Pentiuk S, Putnam PE, Collins MH, Rothenberg ME: Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009, 48:152-60.

F1000 Factor 6.0 Must Read
Evaluated by Jonathan Spergel 09 Mar 2009

33. Mulder DJ, Pacheco I, Hurlbut DJ, Mak N, Furuta GT, MacLeod RJ, Justinich CJ: FGFR9-induced proliferative response to eosinophilic inflammation in eosinophilic esophagitis. Gut 2009, 58:166-73.

34. Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, Blanchard C, Putnam PE, Rothenberg ME: Eosophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 2008, 134:204-14.

35. Bullock JZ, Villanueva JM, Blanchard C, Filipovich AH, Putnam PE, Collins MH, Risma KA, Akers RM, Kirby CL, Buckmeier BK, Assa’ad AH, Hogan SP, Rothenberg ME: Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2007, 45:22-31.

36. Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME: IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 2007, 120:1292-300.

F1000 Factor 3.0 Recommended
Evaluated by Jonathan Spergel 18 Feb 2008

37. Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU: Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008, 122:425-7.